8-K: Charlotte's Web Reports Mixed Q2 Results, Launches New E-commerce Platform and Reduces Expenses

Charlotte's Web reported a decrease in revenue for the second quarter of 2024, but also launched a new e-commerce platform and implemented cost-cutting measures.

Summary

• Charlotte's Web reported a net revenue of $12.3 million for the second quarter of 2024, down from $16.0 million in the same period last year.
• The company's gross profit was $2.6 million, or 21.0% of revenue, impacted by a $3.8 million non-cash inventory provision.
• Excluding the inventory provision, the adjusted gross margin was 52.2% for Q2 2024, compared to 56.5% in Q2 2023.
• Direct-to-consumer (DTC) net revenue was $7.8 million, a decrease of 27.1% year-over-year, but increased 0.6% quarter-over-quarter.
• Business-to-business (B2B) net revenue was $4.4 million, a decrease of 16.6% year-over-year, but increased 8.8% quarter-over-quarter.
• The company launched a new e-commerce platform in June 2024 to improve customer experience and marketing capabilities.
• Selling, general, and administrative (SG&A) expenses decreased by 25.0% to $14.7 million compared to $19.6 million in Q2 2023.
• The company expects SG&A expenses for 2024 to be more than $20 million lower than 2023.
• Charlotte's Web reported a net loss of $11.0 million for Q2 2024, compared to a net income of $2.8 million in Q2 2023.
• Adjusted EBITDA loss for Q2 2024 was $5.2 million, compared to an Adjusted EBITDA of $3.7 million in Q2 2023.
• The company's cash and working capital as of June 30, 2024, were $32.5 million and $38.5 million, respectively.
• The company expects to achieve cash flow breakeven at approximately $65 million in annual net revenue with the refined cost structure.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with both positive developments (e-commerce launch, cost reductions) and negative results (revenue decline, net loss). The sentiment is neutral to slightly negative due to the financial performance, but the cost cutting and new initiatives provide some optimism.

Positives

• The new e-commerce platform is performing well and has enhanced the consumer experience.
• Retail business showed improvement with the first sequential second-quarter growth since 2021.
• Distribution gains were achieved, including with Walmart, and new products were launched.
• Significant reductions in operating expenses were made, with more than $20 million expected in savings for 2024.
• The company is working towards achieving cash flow breakeven at approximately $65 million in annual net revenue.
• DeFloria's Phase 1 trial data is nearing completion, with plans to submit an IND application to the FDA.
• The company is actively supporting legislation that could positively impact the hemp and CBD industries.
• Retail distribution in the Natural channel increased by 10% year-over-year.

Negatives

• Consolidated net revenue decreased to $12.3 million in Q2 2024 from $16.0 million in Q2 2023.
• Gross profit was reduced to $2.6 million due to a $3.8 million non-cash inventory provision.
• Direct-to-consumer net revenue decreased by 27.1% year-over-year.
• Business-to-business net revenue decreased by 16.6% year-over-year.
• The company reported a net loss of $11.0 million for Q2 2024, compared to a net income of $2.8 million in Q2 2023.
• Adjusted EBITDA loss for Q2 2024 was $5.2 million, compared to an Adjusted EBITDA of $3.7 million in Q2 2023.
• Net cash used for operations was $4.7 million in Q2 2024, compared to $1.0 million cash provided in Q2 2023.

Risks

• The CBD industry is facing ongoing headwinds, including regulatory ambiguities and competitive alternatives.
• The company experienced lower online traffic and new consumer acquisitions, impacting DTC revenue.
• Reductions in retail shelf space allocated to the CBD category impacted B2B revenue.
• Inflationary impact on discretionary consumer spending and product mix shifts also contributed to revenue declines.
• The company's cash and working capital have decreased compared to December 31, 2023.
• The company is subject to risks and uncertainties related to supply and distribution chains, market conditions, regulatory changes, and competition.

Future Outlook

The company expects a reduction in SG&A for 2024 of more than $20 million from 2023 and aims to achieve cash flow breakeven at approximately $65 million in annual net revenue. They also anticipate the potential for a Phase 2 clinical trial program with DeFloria.

Management Comments

• Bill Morachnick, Chief Executive Officer, stated that strategic turnaround initiatives and innovations are yielding promising results towards a return to growth, despite lower revenue.
• Erika Lind, Chief Financial Officer, mentioned that additional measures were taken to further align with current revenue levels and decrease future cash burn.

Industry Context

The announcement reflects the challenges faced by the broader CBD industry, including regulatory uncertainties and competitive pressures. The company's efforts to reduce costs and improve its e-commerce platform are in line with industry trends to adapt to these challenges.

Comparison to Industry Standards

• While Charlotte's Web is a market leader, the revenue decline indicates that they are not immune to the broader industry challenges.
• The company's adjusted gross margin of 52.2% is comparable to other established players in the consumer packaged goods space, but the decline from 56.5% in the previous year is a concern.
• The company's focus on cost reduction and e-commerce improvements mirrors strategies employed by other companies in the sector, such as Canopy Growth and Tilray, who are also working to achieve profitability.
• The expansion into Walmart is a positive step, similar to other CBD companies seeking broader distribution channels, such as Curaleaf's partnerships with CVS and other major retailers.
• The DeFloria partnership and clinical trial efforts are unique and could provide a competitive advantage if successful, similar to GW Pharmaceuticals' development of Epidiolex.

Stakeholder Impact

• Shareholders will be concerned about the revenue decline and net loss, but may be encouraged by the cost-cutting measures and new initiatives.
• Employees may be impacted by the cost reductions, but the company's focus on growth could provide future opportunities.
• Customers should benefit from the improved e-commerce platform and new product offerings.
• Suppliers may be affected by the company's efforts to reduce costs.
• Creditors will be monitoring the company's cash flow and financial performance.

Next Steps

• The company will continue to focus on improving its e-commerce platform and customer experience.
• They will continue to implement cost-cutting measures to reduce cash burn.
• The company will work towards achieving cash flow breakeven at approximately $65 million in annual net revenue.
• DeFloria will submit its IND application to the FDA later this year.
• The company will continue to support legislative efforts to regulate hemp extract products.
• Management will host a conference call to discuss the results.

Key Dates

Keywords

CBD, hemp, e-commerce, retail, revenue, cost reduction, FDA, DeFloria, SG&A, EBITDA, Walmart, gummies, legislation